The "tricky business" of identifying mechanisms of resistance to anti-PD-1

James S. Wilmott, Helen Rizos, Richard A. Scolyer, Georgina V. Long*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    5 Citations (Scopus)


    Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them.

    Original languageEnglish
    Pages (from-to)2921-2923
    Number of pages3
    JournalClinical Cancer Research
    Issue number12
    Publication statusPublished - 15 Jun 2017


    Dive into the research topics of 'The "tricky business" of identifying mechanisms of resistance to anti-PD-1'. Together they form a unique fingerprint.

    Cite this